Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Prolor Biotech Climbs Most in Two Weeks on Trial Update

May 7 (Bloomberg) -- Prolor Biotech Inc. gained the most in two weeks after results from an extended Phase II trial of hGH-CTP human growth hormone showed a single weekly treatment may replace daily injections and was safe.

The shares jumped 3.8 percent, the most since April 22, to 20.89 shekels at the 4:30 p.m. close in Tel Aviv.

To contact the reporter on this story: David Wainer in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.